PharmaResearch signed a June 2026 deal to acquire CG USA and build US manufacturing for its Rejuran PDRN line. The injectable skin booster is not FDA-approved.
PharmaResearch signed a deal on June 30, 2026 to acquire California manufacturer CG USA, building US production for its Rejuran polynucleotide (PDRN) brand as it expands through Sephora and Amazon. The retail line is topical, but the Rejuran injectable is not FDA-approved and is used off-label through compounding.
PharmaResearch, the South Korean regenerative-medicine company behind the Rejuran brand, has signed an agreement to acquire Cosmetic Group USA (CG USA), a California-based cosmetics manufacturer, to build a local production base for its Rejuran polynucleotide (PDRN) product line. The deal was signed on June 30, 2026, and financial terms were not disclosed.
The acquisition follows Rejuran's US retail launch at Sephora and its expanding presence on Amazon. It is important to separate the two forms sold under this brand. The retail Rejuran Cosmetics line is topical and cosmetic-grade. The Rejuran injectable skin booster, by contrast, is not FDA-approved in the US and is used off-label, often through compounded or imported product.
PharmaResearch signed the agreement to acquire CG USA on June 30, 2026, according to the company's announcement. CG USA, founded in 1986 and based in Los Angeles, operates an FDA-registered facility, holds ISO 22716 certification, and maintains a quality system aligned with current good manufacturing practice (cGMP) standards for over-the-counter products. It provides product planning, formula development, manufacturing, filling, packaging, and quality control. Cosmo Group advised on the transaction, and terms were not disclosed.
CEO Ji Hoon Sohn said the acquisition is a strategic decision to strengthen supply stability and build a stronger foundation for business expansion in North America. The Rejuran Cosmetics line is built around DOT c-PDRN, PharmaResearch's patented cosmetic-grade polynucleotide ingredient. The company also plans to enter Canada in the second half of 2026 as part of a broader Americas expansion.
A US manufacturing base addresses supply stability, not regulatory approval. Building a domestic plant does not change the FDA status of any product. Topical cosmetics do not require FDA pre-market approval, which is why the Rejuran Cosmetics retail line can be sold at Sephora and on Amazon.
Injectable polynucleotide and PDRN skin boosters are a separate category. No PN or PDRN injectable, including Rejuran, is FDA-approved for cosmetic use in the US. Clinics that offer these injections do so off-label, sometimes using imported or compounded product, which carries legal and safety considerations. This distinction is the core fact for anyone researching Rejuran: the brand name spans both a legal topical range and an injectable that US regulators have not approved. A manufacturing deal is not evidence that the injectable has been cleared for US use.
Watch whether PharmaResearch's Canada entry proceeds in the second half of 2026 and how the deal formally closes. Watch whether US production expands beyond topical cosmetics, since the injectable's regulatory status remains unchanged. Evidence for polynucleotide skin boosters is still limited, and any FDA pathway for the injectable would be a separate, multi-year process. For now, the news concerns manufacturing and retail distribution of a cosmetic line, not approval of a medical injectable. Anyone considering an in-clinic Rejuran treatment should confirm exactly what product a provider uses and its regulatory status before proceeding.